Unews World
Potential tariff on pharma imports into the US, while still under Section 232 investigation, is unlikely to impact the credit profiles of Indian pharma companies, India Ratings and Research (Ind-Ra) said.While the US contributes around 35% to the total revenue for leading domestic pharma companies, this proportion has been steadily declining over the past few years due to price erosion …
Read More »`Indian pharma resilient to potential US tariffs’ – Times of India
